Warner Chilcott forecast disappoints market; EMA launches probe into Bayer's Diane 35;

@FiercePharma: Turns out, Vivus' slow launch of Qsymia may be best plan. News | Follow @FiercePharma

@EricPFierce: Sun tells Taro shareholders to forget it, cancels $685 million offer for Israeli generic drug player. Report | Follow @EricPFierce

@AlisonBFierce: Evidence of a link between GSK's Pandemrix and a spike in narcolepsy cases is putting AS03 under intense scrutiny. More | Follow @AlisonBFierce

> Specialty drugmaker Warner Chilcott ($WCRX) disappointed analysts today, saying generic competition for osteoporosis treatment Actonel will hurt sales this year. Story

> The European Medicines Agency has officially launched a safety review of Bayer's acne pill Diane 35 and its generic versions, after being asked by France to look more deeply at ties to blood clots. Story

> A Florida man has pleaded guilty to importing unapproved cancer drugs into the U.S. Release

> Swiss officials are taking steps to curb the influence of drug companies on doctors with new rules. Item

 @FierceMedDev: Ultrasound elastography eyed as cancer Dx method. Report | Follow @FierceMedDev

 @MarkHFierce: India is competing with the larger device companies by launching firms that make cheaper, quality alternatives. News | Follow @MarkHFierce

 @DamianFierce: LabCorp joins the list of diagnostics providers expecting Medicare cuts to take a bite out of 2013 revenue. Story | Follow @DamianFierce

> India's med device outfits beat multinationals on price. News

> Insulet ditches DexCom in diabetes collaboration. Article

Biotech News

 @FierceBiotech: Pfizer to lop off Asian research unit amid major R&D downsizing. Story | Follow @FierceBiotech

@RyanMFierce: Troubled biotech Tranzyme mulls potential sale after R&D face plants. More | Follow @RyanMFierce

> French biotech rapidly stuck on losing side of hep C revolution. News

> A new wave of biotechs takes shape in the U.K. Editor's Corner

> Oncolytics Biotech surges on lung cancer data. Story

And Finally... Merck ($MRK) Consumer Care Chief Bridgette Heller has been named Woman of the Year by the Healthcare Businesswomen's Association. More

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.